Indication
Endometrial Adenocarcinoma
2 clinical trials
3 products
Clinical trial
A Phase 2b, Open-label, Single Arm, Multicentre, Pilot Study of the Efficacy, Safety and Tolerability of Dostarlimab in Women With Early-stage MMR Deficient Endometrioid Endometrial Adenocarcinoma.Status: Not yet recruiting, Estimated PCD: 2026-06-30
Product
Dostarlimab-GxlyClinical trial
Phase II Study of Fulvestrant in Combination With Abemaciclib in Hormone Receptor Positive Adenocarcinoma of EndometriumStatus: Active (not recruiting), Estimated PCD: 2026-08-01
Product
FulvestrantProduct
Abemaciclib